Abstract
Abatacept is a fusion protein (CTLA4-Ig) and therapeutic molecule labeled for the treatment of rheumatoid arthritis (RA). Abatacept acts both by disrupting the CD28-mediated activation of T cells and by interacting with CD80/CD86 molecules present on antigen presenting cells such as monocytes and memory B cells. Accordingly and to evaluate clinical and biological parameters associated with response to abatacept, a retrospective monocentric study was conducted in 43 patients with RA, and the clinical response was evaluated at 6 months according to EULAR response criteria. Median age of the patients was 59.8 ± 15.1 years including 35 females and 8 males. At baseline, no difference was observed between non-responders (NR, n = 11), moderate responders (MR, n = 21), and good responders (GR, n = 11) to abatacept with regards to demographic, biological, and clinical characteristics of the patients (age, sex, anti-CCP, RF, FcγR3A V158F polymorphism, and C3/C4 complement reduction). Moreover, peripheral blood lymphocyte phenotyping was performed by flow cytometry revealing in 30 RA patients compared to controls (n = 45; median age 56.7 ± 13.5 years) that the initial CD19+ B cell count was reduced in NR and MR but not in GR. No differences were observed with regards to total lymphocyte, T cell, and NK cell counts. Next, we further explored the effects of abatacept on B cell subsets (IgD/CD38 in panel 1 and IgD/CD27 in panel 2) and observed that the basal level of CD38+ and/or CD27+ memory B cell count was important for an abatacept response and that a selective effect of abatacept was observed on memory B cells after 6 months. In conclusion, and although these data need to be confirmed in an independent cohort, our data support a role for memory B cells in the mechanism of action of abatacept in RA.
Similar content being viewed by others
References
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis & Rheumatism 31(3):315–324
Kourilovitch M, Galarza-Maldonado C, Ortiz-Prado E (2014) Diagnosis and classification of rheumatoid arthritis. J Autoimmun 48-49:26–30. doi:10.1016/j.jaut.2014.01.027
Mikuls TR, Payne JB, Deane KD, Thiele GM (2016) Autoimmunity of the lung and oral mucosa in a multisystem inflammatory disease: the spark that lights the fire in rheumatoid arthritis? J Allergy Clin Immunol 137(1):28–34. doi:10.1016/j.jaci.2015.10.024
Arleevskaya MI, Kravtsova OA, Lemerle J, Renaudineau Y, Tsibulkin AP (2016) How rheumatoid arthritis can result from provocation of the immune system by microorganisms and viruses. Front Microbiol 7:1296. doi:10.3389/fmicb.2016.01296
Lemerle J, Arleevskaya MI, Brooks WH, Renaudineau Y (2016) Effects of environmental factors and omega-3 fatty acids on rheumatoid arthritis. Annals of Joint:1–4
Shapira Y, Agmon-Levin N, Shoenfeld Y (2010) Geoepidemiology of autoimmune rheumatic diseases. Nat Rev Rheumatol 6(8):468–476. doi:10.1038/nrrheum.2010.86
Konsta OD, Le Dantec C, Charras A, Brooks WH, Arleevskaya MI, Bordron A, Renaudineau Y (2015) An in silico approach reveals associations between genetic and epigenetic factors within regulatory elements in B cells from primary Sjogren’s syndrome patients. Front Immunol 6:437. doi:10.3389/fimmu.2015.00437
Brooks WH, Le Dantec C, Pers JO, Youinou P, Renaudineau Y (2010) Epigenetics and autoimmunity. J Autoimmun 34(3):J207–J219. doi:10.1016/j.jaut.2009.12.006
Konsta OD, Le Dantec C, Brooks WH, Renaudineau Y (2001) Genetics and Epigenetics of Autoimmune Diseases. In: eLS. John Wiley & Sons, Ltd. doi:10.1002/9780470015902.a0023593
Lu Q, Renaudineau Y, Cha S, Ilei G, Brooks WH, Selmi C, Tzioufas A, Pers JO, Bombardieri S, Gershwin ME, Gay S, Youinou P (2010) Epigenetics in autoimmune disorders: highlights of the 10th Sjogren’s syndrome symposium. Autoimmun Rev 9(9):627–630. doi:10.1016/j.autrev.2010.05.011
Zampeli E, Vlachoyiannopoulos PG, Tzioufas AG (2015) Treatment of rheumatoid arthritis: unraveling the conundrum. J Autoimmun 65:1–18. doi:10.1016/j.jaut.2015.10.003
Favalli EG, Biggioggero M, Meroni PL (2014) Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an "anchor" drug? Autoimmun Rev 13(11):1102–1108. doi:10.1016/j.autrev.2014.08.026
Her M, Kavanaugh A (2016) Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol 137(1):19–27. doi:10.1016/j.jaci.2015.10.023
Kivity S, Zafrir Y, Loebstein R, Pauzner R, Mouallem M, Mayan H (2014) Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients. Autoimmun Rev 13(11):1109–1113. doi:10.1016/j.autrev.2014.08.027
Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, Jayne DR (2015) Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun 57:60–65. doi:10.1016/j.jaut.2014.11.009
Cambridge G, Perry HC, Nogueira L, Serre G, Parsons HM, De La Torre I, Dickson MC, Leandro MJ, Edwards JC (2014) The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment. J Autoimmun 50:67–76. doi:10.1016/j.jaut.2013.12.002
Samavedam UK, Kalies K, Scheller J, Sadeghi H, Gupta Y, Jonkman MF, Schmidt E, Westermann J, Zillikens D, Rose-John S, Ludwig RJ (2013) Recombinant IL-6 treatment protects mice from organ specific autoimmune disease by IL-6 classical signalling-dependent IL-1ra induction. J Autoimmun 40:74–85. doi:10.1016/j.jaut.2012.08.002
Iannone F, Lopalco G, Rigante D, Orlando I, Cantarini L, Lapadula G (2016) Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy. Autoimmun Rev. doi:10.1016/j.autrev.2016.01.010
Zhang Z, Zhang R (2015) Epigenetics in autoimmune diseases: pathogenesis and prospects for therapy. Autoimmun Rev 14(10):854–863. doi:10.1016/j.autrev.2015.05.008
Sakkas LI, Bogdanos DP, Katsiari C, Platsoucas CD (2014) Anti-citrullinated peptides as autoantigens in rheumatoid arthritis-relevance to treatment. Autoimmun Rev 13(11):1114–1120. doi:10.1016/j.autrev.2014.08.012
Garaud S, Le Dantec C, Jousse-Joulin S, Hanrotel-Saliou C, Saraux A, Mageed RA, Youinou P, Renaudineau Y (2009) IL-6 modulates CD5 expression in B cells from patients with lupus by regulating DNA methylation. J Immunol 182(9):5623–5632. doi:10.4049/jimmunol.0802412
Thabet Y, Le Dantec C, Ghedira I, Devauchelle V, Cornec D, Pers JO, Renaudineau Y (2013) Epigenetic dysregulation in salivary glands from patients with primary Sjogren’s syndrome may be ascribed to infiltrating B cells. J Autoimmun 41:175–181. doi:10.1016/j.jaut.2013.02.002
Thabet Y, Canas F, Ghedira I, Youinou P, Mageed RA, Renaudineau Y (2012) Altered patterns of epigenetic changes in systemic lupus erythematosus and auto-antibody production: is there a link? J Autoimmun 39(3):154–160. doi:10.1016/j.jaut.2012.05.015
Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, Cohen S, Luggen M, Shergy W, Nuamah I, Becker JC (2002) Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis & Rheumatism 46(6):1470–1479. doi:10.1002/art.10294
Atzeni F, Sarzi-Puttini P, Mutti A, Bugatti S, Cavagna L, Caporali R (2013) Long-term safety of abatacept in patients with rheumatoid arthritis. Autoimmun Rev 12(12):1115–1117. doi:10.1016/j.autrev.2013.06.011
Romo-Tena J, Gomez-Martin D, Alcocer-Varela J (2013) CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance. Autoimmun Rev 12(12):1171–1176. doi:10.1016/j.autrev.2013.07.002
Bonelli M, Ferner E, Goschl L, Bluml S, Hladik A, Karonitsch T, Kiener HP, Byrne R, Niederreiter B, Steiner CW, Rath E, Bergmann M, Smolen JS, Scheinecker C (2013) Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis. Arthritis & Rheumatism 65(3):599–607. doi:10.1002/art.37787
Axmann R, Herman S, Zaiss M, Franz S, Polzer K, Zwerina J, Herrmann M, Smolen J, Schett G (2008) CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis 67(11):1603–1609. doi:10.1136/ard.2007.080713
Ranheim EA, Kipps TJ (1994) Elevated expression of CD80 (B7/BB1) and other accessory molecules on synovial fluid mononuclear cell subsets in rheumatoid arthritis. Arthritis & Rheumatism 37(11):1637–1646
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis & Rheumatism 62(9):2569–2581. doi:10.1002/art.27584
Gazeau P, Devauchelle-Pensec V, Pochard P, Pers JO, Saraux A, Renaudineau Y, Cornec D (2015) Abatacept efficacy in rheumatoid arthritis is dependent upon baseline blood B-cell levels. Rheumatology (Oxford). doi:10.1093/rheumatology/kev417
Fransen J, van Riel PL (2005) The disease activity score and the EULAR response criteria. Clin Exp Rheumatol 23(5 Suppl 39):S93–S99
van Gestel AM, Haagsma CJ, van Riel PL (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis & Rheumatism 41(10):1845–1850. doi:10.1002/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K
Taylor WJ, Harrison AA, Highton J, Chapman P, Stamp L, Dockerty J, McQueen F, Jones PB, Ching D, Porter D, Rajapakse C, Rudge SR, Taylor G, Kumar S, Macedo T, Hoy MS (2008) Disease activity score 28-ESR bears a similar relationship to treatment decisions across different rheumatologists, but misclassification is too frequent to replace physician judgement. Rheumatology (Oxford) 47(4):514–518. doi:10.1093/rheumatology/ken004
Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, Aletaha D, van Riel PL (2009) Validation of the 28-joint disease activity score (DAS28) and European league against rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 68(6):954–960. doi:10.1136/ard.2007.084459
Croquefer S, Renaudineau Y, Jousse S, Gueguen P, Ansart S, Saraux A, Youinou P (2005) The ananti-alpha-actinin test completes ananti-DNA determination in systemic lupus erythematosus. Ann N Y Acad Sci 1050:170–175. doi:10.1196/annals.1313.017
Renaudineau Y, Jamin C, Saraux A, Youinou P (2005) Rheumatoid factor on a daily basis. Autoimmunity 38(1):11–16. doi:10.1080/08916930400022574
Renaudineau Y, Croquefer S, Jousse S, Renaudineau E, Devauchelle V, Gueguen P, Hanrotel C, Gilburd B, Saraux A, Shoenfeld Y, Putterman C, Youinou P (2006) Association of alpha-actinin-binding anti-double-stranded DNA antibodies with lupus nephritis. Arthritis & Rheumatism 54(8):2523–2532. doi:10.1002/art.22015
Bohnhorst JO, Bjorgan MB, Thoen JE, Natvig JB, Thompson KM (2001) Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren’s syndrome. J Immunol 167(7):3610–3618
Alonso R, Buors C, Le Dantec C, Hillion S, Pers JO, Saraux A, Montero E, Marianowski R, Loisel S, Devauchelle V, Youinou P, Renaudineau Y (2010) Aberrant expression of CD6 on B-cell subsets from patients with Sjogren’s syndrome. J Autoimmun 35(4):336–341. doi:10.1016/j.jaut.2010.07.005
Cornec D, Saraux A, Pers JO, Jousse-Joulin S, Marhadour T, Roguedas-Contios AM, Genestet S, Renaudineau Y, Devauchelle-Pensec V (2014) Diagnostic accuracy of blood B-cell subset profiling and autoimmunity markers in Sjogren’s syndrome. Arthritis research & therapy 16(1):R15. doi:10.1186/ar4442
Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S, Roudaut A, Jamin C, Renaudineau Y, Roue IQ, Cochener B, Youinou P, Saraux A (2007) Improvement of Sjogren’s syndrome after two infusions of rituximab (anti-CD20). Arthritis & Rheumatism 57(2):310–317. doi:10.1002/art.22536
Cornec D, Tempescul A, Querellou S, Hutin P, Pers JO, Jamin C, Bendaoud B, Berthou C, Renaudineau Y, Youinou P (2012) Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy. Ann Hematol 91(5):715–721. doi:10.1007/s00277-011-1369-y
Tempescul A, Bagacean C, Riou C, Bendaoud B, Hillion S, Debant M, Buors C, Berthou C, Renaudineau Y (2015) Ofatumumab capacity to deplete B cells from chronic lymphocytic leukaemia is affected by C4 complement exhaustion. European journal of haematology. doi:10.1111/ejh.12573
Renaudineau Y, Devauchelle-Pensec V, Hanrotel C, Pers JO, Saraux A, Youinou P (2009) Monoclonal anti-CD20 antibodies: mechanisms of action and monitoring of biological effects. Joint Bone Spine 76(5):458–463. doi:10.1016/j.jbspin.2009.03.010
Seret G, Hanrotel C, Bendaoud B, Le Meur Y, Renaudineau Y (2013) Homozygous FCGR3A-158F mutation is associated with delayed B-cell depletion following rituximab but with preserved efficacy in a patient with refractory lupus nephritis. Clin Kidney J 6(1):74–76. doi:10.1093/ckj/sfs162
Daien CI, Gailhac S, Mura T, Combe B, Hahne M, Morel J (2014) High levels of memory B cells are associated with response to a first tumor necrosis factor inhibitor in patients with rheumatoid arthritis in a longitudinal prospective study. Arthritis research & therapy 16(2):R95. doi:10.1186/ar4543
Sellam J, Rouanet S, Hendel-Chavez H, Abbed K, Sibilia J, Tebib J, Le Loet X, Combe B, Dougados M, Mariette X, Taoufik Y (2011) Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Arthritis & Rheumatism 63(12):3692–3701. doi:10.1002/art.30599
Mahmood Z, Muhammad K, Schmalzing M, Roll P, Dorner T, Tony HP (2015) CD27-IgD- memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis. Arthritis research & therapy 17:61. doi:10.1186/s13075-015-0580-y
Moller B, Aeberli D, Eggli S, Fuhrer M, Vajtai I, Vogelin E, Ziswiler HR, Dahinden CA, Villiger PM (2009) Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis. Arthritis research & therapy 11(3):R62. doi:10.1186/ar2686
Adlowitz DG, Barnard J, Biear JN, Cistrone C, Owen T, Wang W, Palanichamy A, Ezealah E, Campbell D, Wei C, Looney RJ, Sanz I, Anolik JH (2015) Expansion of activated peripheral blood memory B cells in rheumatoid arthritis, impact of B cell depletion therapy, and biomarkers of response. PLoS One 10(6):e0128269. doi:10.1371/journal.pone.0128269
Daien CI, Duny Y, Barnetche T, Daures JP, Combe B, Morel J (2012) Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis 71(6):862–868. doi:10.1136/annrheumdis-2011-201148
Gazeau P, Devauchelle-Pensec V, Pochard P, Pers JO, Saraux A, Renaudineau Y, Cornec D (2016) Abatacept efficacy in rheumatoid arthritis is dependent upon baseline blood B-cell levels. Rheumatology (Oxford) 55(6):1138–1140. doi:10.1093/rheumatology/kev417
Schreiber K, Nocturne G, Cornec D, Daïen C (2017) Lymphocytes as biomarkers of therapeutic response in rheumatic autoimmune diseases, a realistic goal? Clinical reviews in allergy & immunology:In press
Carvajal Alegria G, Gazeau P, Hillion S, Daïen CI, Cornec D (2017) Could lymphocyte profiling be useful to diagnos systemic autoimmune diseases? Clinical reviews in allergy & immunology:In Press
Seret G, Canas F, Pougnet-Di Costanzo L, Hanrotel-Saliou C, Jousse-Joulin S, Le Meur Y, Saraux A, Valeri A, Putterman C, Youinou P, Rojas-Villarraga A, Anaya JM, Renaudineau Y (2015) Anti-alpha-actinin antibodies are part of the anti-cell membrane antibody spectrum that characterize patients with lupus nephritis. J Autoimmun 61:54–61. doi:10.1016/j.jaut.2015.05.009
Youinou P, Taher TE, Pers JO, Mageed RA, Renaudineau Y (2009) B lymphocyte cytokines and rheumatic autoimmune disease. Arthritis & Rheumatism 60(7):1873–1880. doi:10.1002/art.24665
Renaudineau Y, Pers JO, Bendaoud B, Jamin C, Youinou P (2004) Dysfunctional B cells in systemic lupus erythematosus. Autoimmun Rev 3(7–8):516–523. doi:10.1016/j.autrev.2004.07.035
Bystrom J, Clanchy FI, Taher TE, Al-Bogami M, Mohamed H, Alzabin S, Mangat P, Jawad A, R.O. William, Mageed R (2017) Response to treatment with TNF-alpha inhibitors in rheumatoid arthritis is associated with high levels of GM-CSF and GM-CSF+ T lymphocytes. Clinical reviews in allergy & immunology:In Press
Mohr A, Renaudineau Y, Bagacean C, Pers JO, Jamin C, Bordron A (2016) Regulatory B lymphocyte functions should be considered in chronic lymphocytic leukemia. Oncoimmunology 5(5):e1132977. doi:10.1080/2162402X.2015.1132977
Nouel A, Segalen I, Jamin C, Doucet L, Caillard S, Renaudineau Y, Pers JO, Le Meur Y, Hillion S (2014) B cells display an abnormal distribution and an impaired suppressive function in patients with chronic antibody-mediated rejection. Kidney Int 85(3):590–599. doi:10.1038/ki.2013.457
O’Neill SK, Cao Y, Hamel KM, Doodes PD, Hutas G, Finnegan A (2007) Expression of CD80/86 on B cells is essential for autoreactive T cell activation and the development of arthritis. J Immunol 179(8):5109–5116
Taher TE, Bystrom J, Ong VH, Isenberg D, Y. R, Abraham DJ, Mageed R (2017) Intracellular B lymphocyte signalling and the regulation of humoral immunity and autoimmunity. Clinical reviews in allergy & immunology:In Press
Davis PM, Abraham R, Xu L, Nadler SG, Suchard SJ (2007) Abatacept binds to the fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J Rheumatol 34(11):2204–2210
Bagacean C, Zdrenghea M, Tempescul A, Cristea V, Renaudineau Y (2016) Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises. Immunotherapy 8(5):569–581. doi:10.2217/imt-2015-0015
Youinou P, Hillion S, Jamin C, Pers JO, Saraux A, Renaudineau Y (2006) B lymphocytes on the front line of autoimmunity. Autoimmun Rev 5(3):215–221. doi:10.1016/j.autrev.2005.06.011
Pers JO, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A, Hutin P, Renaudineau Y, Dueymes M, Loisel S, Berthou C, Saraux A, Youinou P (2007) BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren’s syndrome. Arthritis & Rheumatism 56(5):1464–1477. doi:10.1002/art.22603
Berkowska MA, Driessen GJ, Bikos V, Grosserichter-Wagener C, Stamatopoulos K, Cerutti A, He B, Biermann K, Lange JF, van der Burg M, van Dongen JJ, van Zelm MC (2011) Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways. Blood 118(8):2150–2158. doi:10.1182/blood-2011-04-345579
Rodriguez-Bayona B, Ramos-Amaya A, Perez-Venegas JJ, Rodriguez C, Brieva JA (2010) Decreased frequency and activated phenotype of blood CD27 IgD IgM B lymphocytes is a permanent abnormality in systemic lupus erythematosus patients. Arthritis research & therapy 12(3):R108. doi:10.1186/ar3042
Sato S, Fujimoto M, Hasegawa M, Takehara K (2004) Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis & Rheumatism 50(6):1918–1927. doi:10.1002/art.20274
Catalan D, Aravena O, Sabugo F, Wurmann P, Soto L, Kalergis AM, Cuchacovich M, Aguillon JC, Millenium Nucleus on I, Immunotherapy PF (2010) B cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and FcgammaRIIb, which are modulated by anti-tumor necrosis factor therapy. Arthritis research & therapy 12(2):R68. doi:10.1186/ar2985
Roll P, Muhammad K, Schumann M, Kleinert S, Tony HP (2012) RF positivity has substantial influence on the peripheral memory B-cell compartment and its modulation by TNF inhibition. Scand J Rheumatol 41(3):180–185. doi:10.3109/03009742.2011.645056
Acknowledgements
The author expresses gratitude to Simone Forest and Geneviève Michel for their help in typing the paper.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Funding
There is no funding source.
Informed Consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Gazeau, P., Alegria, G.C., Devauchelle-Pensec, V. et al. Memory B Cells and Response to Abatacept in Rheumatoid Arthritis. Clinic Rev Allerg Immunol 53, 166–176 (2017). https://doi.org/10.1007/s12016-017-8603-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-017-8603-x